Skip to main content

Table 3 Overview of additional clinical trials included in evaluation of congestive heart failure (CHF)

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Study number Treatment Patients Background Follow-up (weeks) Reference/NCT number
1218.2 Linagliptin 1, 2.5, 5, 10 mg Placebo; 35 9 None <2 Heise et al. [43]. NCT02183350
1218.3 Linagliptin, 2.5, 5, 10 mg Placebo; 61 16 None 4 Forst et al. [44]. NCT 02183415
1218.5 Linagliptin 0.5, 2.5, 5 mg Placebo; 170 67 None 30 Singh-Franco et al. [45]. NCT00328172
1218.6 Linagliptin 1, 5, 10 mg Placebo; 197 71 Metformin (most received ≥1500 mg/d) 12 Forst et al. [46]. NCT00309608
1218.37 Linagliptin 5 mg Placebo; 40 40 None 4 Rauch et al. [47]. NCT00716092
1264.3 Linagliptin 5 mg Pioglitazone 15, 30, 45 mg Linagliptin + pioglitazone; 105 284 274 None Up to 54 NCT01183013
  1. (Study 1218.20 in table was not included in the additional analysis, as this trial was not placebo-controlled).